Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Harnalidge OCAS 0.4 mg for LUTS/BPH in Patients Unsatisfied with Tamsulosin 0.2 mg
NCT02180789Phase 4Completed
- Sponsor
- Astellas Pharma
- Start
- Mar 2013
- Primary completion
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of Harnalidge in benign prostatic hyperplasia (BPH), sponsored by Astellas Pharma. Started Mar 2013; status: completed.
02
Drugs
Harnalidge
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on NCT02180789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02180789.